Prince Pharmaceutical Co (6935) Fair Value & Analysis
Healthcare · TW · Market cap 1.1B TWD
Fair value as of: Jun 24, 2026
Analysis
Prince Pharmaceutical Co (6935) currently trades at 30.00 TWD, while our model-based Fair Value estimate is 51.49 TWD — implying the stock looks roughly 71.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Prince Pharmaceutical Co., Ltd. manufactures and sells vitamin B1 active pharmaceutical ingredients (APIs) in Taiwan, Japan, Korea, and internationally. The company also offers health food and medicines; vitamin c tablets, vitamin b complex tablets, natto and rhodiola extract capsules, probiotic sachets, and plant extract capsules; and API products comprising felbinac, aldioxa, tulobuterol, ufenamate, bisbentiamine, thiamine disulfide, potassium guaiacolsulfonate, potassium cresolsulfonate, fusultiamine hydrochloride, and fursultiamine. Prince Pharmaceutical Co., Ltd. was founded in 1962 and is headquartered in Yúnlín, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Prince Pharmaceutical Co (6935) undervalued?
What is the fair value of 6935?
What is the quality score of 6935?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.